GlassScriptPhysician profile
Anthony M Omeara
NPI 1821268012
$9,233.14
in general payments reported to CMS, 2019-2025
55 companies · $1,601 in 2025
The $1,601 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $661 · 2021: $1,449 · 2022: $1,343 · 2023: $1,996 · 2024: $1,884 · 2025: $1,601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,394 · Education: $86.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,394.38 |
| Education | $86.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $979.66 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $940.49 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $832.53 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $823.26 | 2021-2025 | |
| Pfizer INC. | $565.82 | 2019-2025 | |
| Amgen INC. | $480.29 | 2020-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $349.07 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Corium, LLC | $301.08 | 2023-2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $294.11 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $274.12 | 2020-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.84 | 2019-2025 | Jardiance |
| Shield Therapeutics INC | $254.40 | 2023-2025 | Accrufer |
| Amarin Pharma, INC. | $225.54 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $220.74 | 2021-2025 | |
| Astellas Pharma US INC | $207.84 | 2020-2024 | Veozah |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Omeara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.